LDCs open-ended waiver of WTO IPRs: drug prices, poverty & more
This article was originally published in Scrip
Executive Summary
Mammoth price differentials between patented and locally produced drugs in a country where nearly 25 million people live in extreme poverty are some of justifications emerging from Bangladesh's promising pharmaceutical industry after the country led Least Developed Country (LDCs) members of the World Trade Organization (WTO) to seek an extension of the transitional period to enforce intellectual property rights on medicines.